Sanofi-Aventis's sales force bears brunt of 927 job cuts
This article was originally published in Scrip
Executive Summary
Sanofi-Aventisis proceeding with the job cuts that it proposed in June, reducing its sales force by 817 representatives and reducing the number of staff at its headquarters in France by 110. The company announced that it planned to cut more than 380 jobs in Germany in January, again among sales representatives, and cut 330 jobs in October 2006. Sanofi-Aventis said that it was considering cutting 700-800 jobs in its domestic operations in June. The cuts follow GlaxoSmithKline's recent decision to cut 850 R&D jobs in the UK and US (Scrip Online, October 1st, 2008). Sanofi-Aventis employs around 28,000 people in France and around 100,000 globally.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.